LUND, Sweden--(BUSINESS WIRE)--Regulatory News: BioInvent International (OMXS: BINV) today announced that the company has been granted a US patent covering the antibody drug candidate BI-505, initially in phase II development for the treatment of multiple myeloma. The patent has broad coverage and protects development of any apoptosis-inducing ICAM-1 antibody.
Help employers find you! Check out all the jobs and post your resume.
